Tetrabenazine (Xenazine) for Huntington's chorea

Medical Letter on Drugs and Therapeutics

Volumn 51, Issue 1304, 2009, Pages 7-8

  Abramowicz, Mark ^o   Zuccotti, Gianna ^a   Pflomm, Jean Marie ^o   Daron, Susan M ^o   Houst, Blaine M ^o   Zanone, Corinne E ^o   Dalton, Vanessa K ^b   Epstein, Eric J ^c   Mukherjee, Sandip K ^d   Hirsch, Jules ^e   Juurlink, David N ^f   Kim, Richard B ^g   Mandell, Gerald L ^h   Meinertz, Hans ⁱ   Roden, Dan M ^j   Simons, F Estelle R ^k   Steigbigel, Neal H ^l   Goodstein, Donna ^o   Faucard, Amy ^o   Covey, Cynthia Macapagal ^o   Schwartz, Lauren K ^m   Cassagnol, Manouchkathe ⁿ   Wong, Susie ^o   Donohue, Liz ^o   Brown, Cheryl ^o   Carbona, Gene ^o   Romatowski, Cristine ^o   Valentino, Joanne F ^o   Wissner Levy, Yosef ^o   more..

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ROCKEFELLER UNIVERSITY   (United States)

^f SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

^h UNIVERSITY OF VIRGINIA   (United States)

ⁱ Mental Health Services CPH   (Denmark)

^j VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF MANITOBA   (Canada)

^l NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁿ ST JOHN'S UNIVERSITY   (United States)

^o NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BENZODIAZEPINE DERIVATIVE; FLUOXETINE; HALOPERIDOL; NEUROLEPTIC AGENT; PAROXETINE; PLACEBO; QUETIAPINE; QUINIDINE; RESERPINE; RISPERIDONE; TETRABENAZINE; ZIPRASIDONE; SLC18A2 PROTEIN, HUMAN; VESICULAR MONOAMINE TRANSPORTER;

AKATHISIA; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DYSPHAGIA; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; HYPOTENSION; MORNING DOSAGE; MOTOR DYSFUNCTION; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSONISM; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; SCHIZOPHRENIA; SEDATION; SHORT SURVEY; SIDE EFFECT; SUICIDE ATTEMPT; ANIMAL; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; METABOLISM; METHODOLOGY; PSYCHOLOGICAL ASPECT; REVIEW;

ANIMALS; CONTROLLED CLINICAL TRIALS AS TOPIC; DEPRESSION; HUMANS; HUNTINGTON DISEASE; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 70349902630     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (6)

1. C Kenney and J Jankovic.Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother 2006; 6:7.
2. WG Ondo et al. Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol 2002; 25:300.
3. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington Disease; a randomized controlled trial. Neurology 2006; 66:366.
4. C Kenney et al. Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov Disord 2007; 22:10.
5. S Frank et al. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol 2008; 31:127.
6. A Fasano et al. The long-term effect of tetrabenazine in the management of Huntington disease. Clin Neuropharmacol 2008; 31:313.